EAM Investors’s Protagonist Therapeutics PTGX Stock Holding History

EAM Investors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.37M	Sell	27,491 -423	-2%	-$44.2K	0.3%	150
2026 Q1	$2.94M	Sell	27,914 -50,584	-64%	-$4.48M	0.34%	140
2025 Q4	$6.86M	Sell	78,498 -1,569	-2%	-$128K	0.76%	15
2025 Q3	$5.23M	Buy	80,067 +8,096	+11%	+$460K	0.6%	52
2025 Q2	$3.98M	Buy	71,971 +2,790	+4%	+$134K	0.6%	79
2025 Q1	$3.35M	Buy	+69,181	New	+$2.9M	0.58%	77
2023 Q3	–	Sell	-87,953	Closed	-$2.43M	–	361
2023 Q2	$2.43M	Buy	+87,953	New	+$2.2M	0.45%	80
2021 Q3	–	Sell	-101,019	Closed	-$4.53M	–	368
2021 Q2	$4.53M	Buy	+101,019	New	+$3.33M	0.7%	10
2021 Q1	–	Sell	-44,067	Closed	-$888K	–	422
2020 Q4	$888K	Sell	44,067 -30,279	-41%	-$652K	0.15%	277
2020 Q3	$1.45M	Buy	+74,346	New	+$1.4M	0.34%	118

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

EAM Investors's PTGX Position: Q2 2026 in Review

EAM Investors reduced its Protagonist Therapeutics (PTGX) stake by 1.5% in Q2 2026, selling an estimated $44.2K and leaving 27,491 shares worth $3.37M. The position accounts for 0.3% of the portfolio, ranked #150.

EAM Investors first reported a position in PTGX in Q3 2020 and has held it in 10 quarters since. The position peaked at $6.86M in Q4 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

EAM Investors held 27,491 shares of Protagonist Therapeutics worth $3.37M as of Q2 2026.
EAM Investors sold 423 Protagonist Therapeutics shares in Q2 2026, an estimated $44.2K.
Protagonist Therapeutics made up 0.3% of EAM Investors's portfolio in Q2 2026, its #150 holding.
EAM Investors first reported a position in Protagonist Therapeutics in Q3 2020 and has held it in 10 quarters since.
EAM Investors's Protagonist Therapeutics position peaked at $6.86M in Q4 2025.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.